<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1645-0086</journal-id>
<journal-title><![CDATA[Psicologia, Saúde & Doenças]]></journal-title>
<abbrev-journal-title><![CDATA[Psic., Saúde & Doenças]]></abbrev-journal-title>
<issn>1645-0086</issn>
<publisher>
<publisher-name><![CDATA[Sociedade Portuguesa de Psicologia da Saúde]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1645-00862023000200491</article-id>
<article-id pub-id-type="doi">10.15309/23psd240206</article-id>
<title-group>
<article-title xml:lang="pt"><![CDATA[Vortioxetina no défice cognitivo ligeiro: revisão de literatura]]></article-title>
<article-title xml:lang="en"><![CDATA[Vortioxetine in mild cognitive impairment: literature review]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ribeiro]]></surname>
<given-names><![CDATA[Sandra]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Santos]]></surname>
<given-names><![CDATA[Joaquim]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Fróis]]></surname>
<given-names><![CDATA[Ana Teresa]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mendes]]></surname>
<given-names><![CDATA[Joana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,ACeS Porto Ocidental USF Aníbal Cunha ]]></institution>
<addr-line><![CDATA[Porto ]]></addr-line>
<country>Portugal</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,ACeS Porto Ocidental USF Bom Porto ]]></institution>
<addr-line><![CDATA[Porto ]]></addr-line>
<country>Portugal</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,ULS Matosinhos USF Horizonte ]]></institution>
<addr-line><![CDATA[Matosinhos ]]></addr-line>
<country>Portugal</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,ACeS Espinho/Gaia USF S. Félix-Perosinho ]]></institution>
<addr-line><![CDATA[Vila Nova de Gaia ]]></addr-line>
<country>Portugal</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>08</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>08</month>
<year>2023</year>
</pub-date>
<volume>24</volume>
<numero>2</numero>
<fpage>491</fpage>
<lpage>497</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_arttext&amp;pid=S1645-00862023000200491&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_abstract&amp;pid=S1645-00862023000200491&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_pdf&amp;pid=S1645-00862023000200491&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo défice cognitivo ligeiro define-se por um estadio intermédio entre a cognição normal e a demência. Os tratamentos farmacológicos para esta condição clínica são escassos e têm uma taxa de eficácia ainda em avaliação. Esta revisão tem como objetivo reunir a atual evidência científica existente acerca do benefício da vortioxetina no défice cognitivo ligeiro. Foi efetuada uma pesquisa de meta-análises, revisões sistemáticas, ensaios clínicos, estudos observacionais e normas de orientação clínica indexados nas bases de dados eletrónicas MEDLINE/Pubmed, The Cochrane Library, Database of Abstracts of Reviews of Effects, National Guideline Clearinghouse, BMJ Evidence-Based Medicine, National Institute for Health and Care Excellence, Canadian Medical Association Practice Guidelines Infobase e Bandolier, utilizando-se os termos MeSH &#8220;Vortioxetine&#8221; e &#8220;Cognitive Dysfunction&#8221;. Não houve nenhuma restrição linguística nos artigos selecionados. O nível de evidência e a força de recomendação foram avaliados utilizando a escala Strength of Recommendation Taxonomy (SORT), da American Academy of Family Physicians. Da pesquisa inicial foram obtidos 127 artigos. Destes, após aplicação dos critérios de inclusão e exclusão, foram excluídos 125, pelo que foram incluídos nesta revisão dois artigos. Estes demostraram que a terapêutica com vortioxetina parece ser mais eficaz do que o placebo na obtenção de melhoria da função cognitiva em indivíduos com défice cognitivo ligeiro, pelo que a sua utilização pode ser benéfica em indivíduos sem contraindicação à sua utilização (Força de Recomendação B). No entanto, são necessários estudos mais robustos para comprovar este benefício.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract Mild cognitive impairment is a stage between the cognitive alterations and an initial stage of dementia. Pharmacologic treatments for this condition are scarce and their efficacy is still under assessment. This review aims at gathering existing scientific evidence regarding the benefits of vortioxetine in mild cognitive impairment. The research included metanalyses, systematic reviews, clinical trials, observational studies, and guidelines indexed in MEDLINE/Pubmed, The Cochrane Library, Database of Abstracts of Reviews of Effects (DARE), National Guideline Clearinghouse, BMJ Evidence-Based Medicine (BMJ EBM), National Institute for Health and Care Excellence (NICE), Canadian Medical Association Practice Guidelines Infobase, and Bandolier, using MeSH terms &#8220;Vortioxetine&#8221; and &#8220;Cognitive Dysfunction&#8221;. Publications from any linguistic background were considered, with no language restrictions. The evidence level and recommendation strength were defined using the American Academy of Family Physicians&#8217; Strength of Recommendation Taxonomy (SORT). In the original research, 127 articles were found, of which 125 were excluded for not meeting inclusion criteria or for meeting exclusion criteria. In the end, two studies were included in the revision. Both studies showed that vortioxetine appeared more effective than placebo in obtaining an improvement of cognitive function in individuals with mild cognitive impairment, thus it may be beneficial in those without contraindications to its use (Strength of Recommendation B). However, further studies are needed to prove this benefit.]]></p></abstract>
<kwd-group>
<kwd lng="pt"><![CDATA[Défice Cognitivo Ligeiro]]></kwd>
<kwd lng="pt"><![CDATA[Vortioxetina]]></kwd>
<kwd lng="pt"><![CDATA[Revisão]]></kwd>
<kwd lng="en"><![CDATA[Cognitive Dysfunction]]></kwd>
<kwd lng="en"><![CDATA[Vortioxetine]]></kwd>
<kwd lng="en"><![CDATA[Review]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="book">
<collab>American Psychiatric Association</collab>
<source><![CDATA[Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR)]]></source>
<year>2022</year>
<publisher-name><![CDATA[American Psychiatric Association Publishing]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brodziak]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Woli&#324;ska]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Ko&#322;at]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Ró&#380;yk-Myrta]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guidelines for Prevention and Treatment of Cognitive Impairment in the Elderly]]></article-title>
<source><![CDATA[Medical Science Monitor]]></source>
<year>2015</year>
<volume>21</volume>
<page-range>585-97</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dilliott]]></surname>
<given-names><![CDATA[A. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Sunderlandc]]></surname>
<given-names><![CDATA[K. M.]]></given-names>
</name>
<name>
<surname><![CDATA[McLaughlind]]></surname>
<given-names><![CDATA[P. M.]]></given-names>
</name>
<name>
<surname><![CDATA[Roberts]]></surname>
<given-names><![CDATA[A. C.]]></given-names>
</name>
<name>
<surname><![CDATA[Evans]]></surname>
<given-names><![CDATA[E. C.]]></given-names>
</name>
<name>
<surname><![CDATA[Abrahao]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Malcolm]]></surname>
<given-names><![CDATA[A. B.]]></given-names>
</name>
<name>
<surname><![CDATA[Black]]></surname>
<given-names><![CDATA[S. E.]]></given-names>
</name>
<name>
<surname><![CDATA[Borrie]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Casaubon]]></surname>
<given-names><![CDATA[L. K.]]></given-names>
</name>
<name>
<surname><![CDATA[Dowlatshahi]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Finger]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Fischer]]></surname>
<given-names><![CDATA[C. E.]]></given-names>
</name>
<name>
<surname><![CDATA[Frank]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Freedman]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Grimes]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Hassan]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Jog]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Kumar]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Hegele]]></surname>
<given-names><![CDATA[R. A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Association of apolipoprotein E variation with cognitive impairment across multiple neurodegenerative diagnoses]]></article-title>
<source><![CDATA[Neurobiology of Aging]]></source>
<year>2021</year>
<volume>105</volume>
</nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="">
<collab>Direção-Geral de Saúde</collab>
<source><![CDATA[Abordagem Terapêutica das Alterações Cognitivas. Norma 053/2011]]></source>
<year>2011</year>
</nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lenze]]></surname>
<given-names><![CDATA[E. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Stevens]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Waring]]></surname>
<given-names><![CDATA[J. D.]]></given-names>
</name>
<name>
<surname><![CDATA[Pham]]></surname>
<given-names><![CDATA[V. T.]]></given-names>
</name>
<name>
<surname><![CDATA[Haddad]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Shimony]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[J. P.]]></given-names>
</name>
<name>
<surname><![CDATA[Bowie]]></surname>
<given-names><![CDATA[C. R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Augmenting Computerized Cognitive Training with Vortioxetine for Age-Related Cognitive Decline: A Randomized Controlled Trial]]></article-title>
<source><![CDATA[The American Journal of Psychiatry]]></source>
<year>2020</year>
<volume>177</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>548-55</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Petersen]]></surname>
<given-names><![CDATA[R. C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mild cognitive impairment: Epidemiology, pathology, and clinical assessment]]></article-title>
<source><![CDATA[UpToDate]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Petersen]]></surname>
<given-names><![CDATA[R. C.]]></given-names>
</name>
<name>
<surname><![CDATA[Lopez]]></surname>
<given-names><![CDATA[O.]]></given-names>
</name>
<name>
<surname><![CDATA[Armstrong]]></surname>
<given-names><![CDATA[M. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Getchius]]></surname>
<given-names><![CDATA[T. S. D.]]></given-names>
</name>
<name>
<surname><![CDATA[Ganguli]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Gloss]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Gronseth]]></surname>
<given-names><![CDATA[G. S.]]></given-names>
</name>
<name>
<surname><![CDATA[Marson]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Pringsheim]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Day]]></surname>
<given-names><![CDATA[G. S.]]></given-names>
</name>
<name>
<surname><![CDATA[Sager]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Stevens]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Alexander Rae-Grant]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology]]></article-title>
<source><![CDATA[Neurology]]></source>
<year>2018</year>
<volume>90</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>126-35</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tan]]></surname>
<given-names><![CDATA[S. N.]]></given-names>
</name>
<name>
<surname><![CDATA[Tan]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Vortioxetine improves cognition in mild cognitive impairment]]></article-title>
<source><![CDATA[Clinical Psychopharmacology]]></source>
<year>2021</year>
<volume>36</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>279-87</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
